Pune, Maharashtra, India, January 19 2021 (Wiredrelease) Prudour Pvt. Ltd –:Market.us, one of the worlds leading by prominent market research firms has released a new recent work on “Prothrombin ...

PARAMUS, N.J., July 26, 2023 – Octapharma USA today announced that Balfaxar ® (prothrombin complex concentrate, human-lans; marketed in Europe and Canada as octaplex ®) has received U.S. Food and Drug ...

Pune, July 22, 2020 (GLOBE NEWSWIRE) -- The global prothrombin complex concentrate (PCC) market size is projected to reach USD 1,604.9 million by 2027, exhibiting a CAGR of 10.6% during the forecast ...

Pune, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Global Prothrombin Complex Concentrate Market size is projected to reach USD 1,604.9 million by 2027, exhibiting a CAGR of 10.6% during the forecast period.

PARAMUS, N.J., April 2, 2025 /PRNewswire/ -- Octapharma USA announced the Journal of the American Medical Association (JAMA) has published results from a Phase III clinical trial, which observed ...

The American Journal of Managed Care® discussed an indirect comparison of andexanet alfa and prothrombin complex concentrate therapy with Alexander T. Cohen, MBBS, MSc, MD, Guy’s and St Thomas’ ...

Octapharma USA is offering Balfaxar (prothrombin complex concentrate, human-lans; marketed in Europe and Canada as octaplex). The new non-activated four factor prothrombin complex concentrate (4F-PCC) ...

About The Study: In this unblinded randomized clinical trial, prothrombin complex concentrate had superior hemostatic efficacy and safety advantages to frozen plasma among patients requiring ...

What is Kcentra®/4-factor Prothrombin Complex Concentrate? Kcentra® (4-factor Prothrombin Complex Concentrate), is a blood clotting factor replacement product. It contains clotting factors II, VII, IX ...

To investigate an appropriate dosing strategy for 4F-PCC (Kcentra; CSL Behring) in obese patients, the authors conducted a retrospective analysis comparing the reversal of warfarin using adjusted ...

PARAMUS, N.J., April 2, 2025 /PRNewswire/ -- Octapharma USA announced the Journal of the American Medical Association (JAMA) has published results from a Phase III clinical trial, which observed ...